SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming utilities, P2E Telegram games, and weekly contests to reward holders. Discussions highlight a potential token burn event at 2500 watchers, alongside the coin's resilience as a Solana survivor meme coin. Community members emphasize active development and ongoing efforts to engage and reward the "Spare Change Army".

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation ($JOBY) is trending amid discussions about its potential participation in the White House's eVTOL Integration Pilot Program and broader market sentiment on pre-revenue companies. While some community members express concerns over valuation and cash burn, others highlight the company's partnerships and progress towards FAA certification, viewing it as a leader in the emerging eVTOL market. Bullish sentiment is fueled by potential catalysts like commercial launches and government support.

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is trending as community members highlight its potential within the Avalanche network, noting its fully diluted supply and predictions of significant influx of RWAs; the overall sentiment suggests a possible run. Some users point to Forbes coverage and increasing TVL as reasons for optimism, while others focus on tokenomics and compare it to other DeFi projects.

Hillenbrand, Inc. is a global industrial company, which engages in providing engineered processing equipment and solutions. It operates through the Advanced Process Solutions and Molding Technology Solutions segments. The Advanced Process Solutions segment provides compounding, extrusion, and material handling, screening, and separating equipment, systems, and services for manufacturing and other industrial processes. The Molding Technology Solutions segment includes engineered and customized equipment, systems, and services in plastic technology and processing. It also operates through the following geographical segments: United States, China, India, Germany, and All Other Countries. The company was founded on November 1, 2007 and is headquartered in Batesville, IN.

Hillenbrand Inc

Hillenbrand ($HI) is trending amid discussions about strategic options, potentially including a sale, and a strong bullish sentiment driven by unusual options activity. The community is actively analyzing the company's consolidation and potential for a significant move, with some speculating about a buyout range. Recent insider buying and high institutional ownership are also contributing to the ongoing interest in the stock.

GME Ethereum

GME Ethereum is trending as the community anticipates a "God Candle" and a tweet from Roaring Kitty, potentially signaling a major surge. Discussions also revolve around JTR Crypto (JTRAMBO) and its recent market cap milestones, with community members emphasizing a "buy and hold" strategy. However, some users are raising concerns about the legitimacy of the project and its affiliation with GameStop.

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARKG is gaining attention as investors discuss potential breakout patterns and compare its performance to other ARK funds, with some expressing frustration over its historical returns. Community members are actively debating entry points and speculating on future catalysts, particularly the impact of AI on genomic advancements. Despite mixed sentiment regarding management, there's anticipation for a potential sector-wide upswing and the impact of future rate cuts.

Green Satoshi Token

GSTSOL is gaining attention as traders discuss its potential for a significant breakout, with some pointing to technical indicators and increasing volume as bullish signals. The community is closely watching for a catalyst that could trigger a rally, while also considering factors like its low market cap and past performance. Sentiment is mixed, with some expressing frustration over previous price action and others remaining optimistic about future gains.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst community disagreement on its potential, with some expressing frustration over its price action relative to Bitcoin's surge and other altcoins. Discussions revolve around potential catalysts, including partnerships and broader market trends, while others dismiss the project as a lost cause, pointing to its ranking decline. The community is split between those who remain optimistic, accumulating more JASMY, and those who are highly critical, predicting further decline.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph ($HBAR) is trending as the community anticipates potential ETF filings and discusses its real-world applications, including integrations with Swift and potential use by Wyoming's "Frontier Stable Token" initiative.  Bullish sentiment is fueled by speculation around upcoming FED rate cuts, with many expecting a surge in altcoins, though some express concern about HBAR's lagging performance compared to other cryptocurrencies.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors discuss its potential for acquisition and its strong position in the AI data engineering space. The community is focused on the company's upcoming Gen AI Summit and Q3 earnings report as potential catalysts, speculating about possible news regarding contracts or a takeover. Some analysts believe $INOD is undervalued compared to its competitors, and the company's move towards "smart data" is also generating buzz.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of MoonLake Immunotherapeutics (MLTX) rebounded 14% on Tuesday after a near 90% plunge on Monday.MoonLake on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/moonlake-stock-crashes-premarket-after-sonelokimab-phase-3-data/chDMDY2R37p">announced</a> 16-week results from its late-stage VELA-1 and VELA-2 identical trials of Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, Sonelokimab achieved statistical significance for all primary and key secondary endpoints, including a substantial improvement in the disease. However, in VELA-2, the drug failed to achieve statistical significance. Subsequently, on Monday, MLTX closed at $6.25, marking its lowest levels in over three years. The stock is currently trading at $7.41.The mixed data drew several price target cuts. Needham analyst Serge Belanger lowered the firm's price target on MoonLake Immunotherapeutics to $20 from $66 on Tuesday, but maintained a ‘Buy’ rating on the shares. The regulatory path looks uncertain, and MoonLake might need to conduct another late-stage trial in the worst-case scenario, the analyst noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_1_04_46_PM_png_2ebbe1ed61.webp" alt="MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rise further.<stembedurl>https://stocktwits.com/Leoheart/message/630505115</stembedurl>Another noted that, although analysts have cut price targets, several targets remain higher than current trading levels.<stembedurl>https://stocktwits.com/Freeballin02/message/630504990</stembedurl>Guggenheim also lowered the firm's price target on the stock to $20 from $80 and kept a ‘Buy’ rating on the shares. While investors are now focused on the drug’s regulatory path, the firm noted that MoonLake is conducting multiple clinical studies across other indications, including palmoplantar pustulosis, psoriatic arthritis, and axial spondyloarthritis. These together sum up to a multibillion-dollar market, the firm noted.Citi analyst Samantha Semenkow, meanwhile, downgraded MoonLake Immunotherapeutics to ‘Neutral’ from ‘Buy’ with a price target of $5, down from $72, on "significant" regulatory risk for the drug. The analyst also noted that Moonlake is currently facing financing challenges.MLTX stock is down by 89% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q">AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Equity

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.


MoonLake Immunotherapeutics shares crashed nearly 90% to record its worst session ever on Monday, as analysts downgraded the stock after the company announced late-stage trial results of its lead drug, sonelokimab, for the treatment of moderate-to-severe hidradenitis suppurativa (HS).By the end of the session, the stock had dropped to $6.25, marking its lowest levels in over three years, before gaining approximately 4.7% in after-hours trading.BTIG downgraded MoonLake to 'Neutral' from 'Buy' and removed the stock from its list of top picks for the second half of the year, saying sonelokimab failed to show differentiation in the Phase 3 VELA-1 and VELA-2 trials. The analyst noted that the placebo-adjusted HiSCR75 results were “well into our worst case scenario” and did not demonstrate a clear efficacy advantage over Bimzelx.Jefferies analyst Clara Dong also downgraded the stock to 'Hold' from 'Buy' and reduced the price target to $8 from $65, citing a smaller commercial opportunity, a lower likelihood of approval despite the drug’s potential path forward, and lesser M&amp;A value.Wolfe Research double-downgraded MoonLake to 'Underperform' from 'Outperform' with a steep price target cut to $2 from $76, saying that even if sonelokimab eventually finds a path forward in HS, realizing stock value “will take too long and will be too tough.”&nbsp;The brokerage firm called the outcome a “surprising MoonLake fiasco,” comparing it to Acelyrin’s collapse after its own HS trial failure, noting that Acelyrin’s stock never rebounded despite later-stage programs in PsA and TED.Leerink Partners highlighted Oruka Therapeutics as a likely beneficiary, noting that its drug, ORKA-002, with a mechanism similar to Bimzelx, could gain traction following MoonLake’s results.&nbsp;On Stocktwits, retail sentiment for MoonLake was ‘extremely bullish’ amid a 4,650% surge in 24-hour message volume.One user expressed confidence in MoonLake’s leadership and long-term outlook, stating that the company has a strong management team and a promising future, with potential for eventual FDA approval.<stembedurl>https://stocktwits.com/HitNRun79/message/630422460</stembedurl>Another user noted that the trial results, while not ideal, still showed meaningful efficacy. They suggested that the sharp decline in the stock was driven more by fear and short-seller activity than by fundamentals, and added that they had taken a position in the stock following the selloff.<stembedurl>https://stocktwits.com/freshstart2021/message/630421221</stembedurl><a href="https://stocktwits.com/symbol/MLTX">MoonLake’s stock</a> has declined 88.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades

Wolfe Research compared MoonLake’s setback to Acelyrin’s HS trial failure, noting that Acelyrin’s stock never rebounded despite later progress in other programs.

MoonLake Immunotherapeutics’ shares plunged about 85% in early premarket trading on Monday after Wall Street analysts panned data from a late-stage trial of its skin drug, setting the stock up for its worst day on record.The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moonlake-immunotherapeutics-stock-buzz-phase-3-skin-drug-sonelokimab-retail-buyout-speculation/chDMkd8R3e6">reported</a> 16-week results from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, sonelokimab patients achieved a 17-percentage-point higher response rate versus placebo; in VELA-2, the gap was 9 points under the composite analysis. Using the treatment-policy approach, both trials showed statistically significant results: 35% and 36% for sonelokimab versus 18% and 26% for placebo.The mixed data disappointed analysts. Stifel cut its rating to ‘Hold’ from ‘Buy’ and slashed its price target to $13 from $77, saying the results were “significantly worse than expected” and trimming its estimated probability of success for the HS indication to 33% from 75%.RBC Capital also downgraded the stock to ‘Sector Perform’ from ‘Outperform’, and lowered its price target to $10 from $67, calling the results a “near-miss” statistically and warning the drug’s effect size looked uncompetitive.Retail traders on Stocktwits took the opposite view, driving sentiment for MLTX to ‘extremely bullish,’ and the mood is poised to hit the highest level of the year.<figure class="image"><a href="https://stocktwits.com/symbol/MLTX"><img style="aspect-ratio:1300/190;" src="https://news.stocktwits-cdn.com/MLTX_stock_sentiment_and_message_volume_Sep_29_premarket_png_916821fc47.webp" alt="MLTX stock sentiment and message volume Sep 29 premarket.png" width="1300" height="190"></a><figcaption>MLTX stock sentiment and message volume Sep 29 premarket. | source: Stocktwits</figcaption></figure>“These kind of monster plunges are a good chance to make an easy 20% trade. Again, despite a disaster, Sono looks approvable and psA is still on deck. Buyer at 7-8 at any time,” said one user.<stembedurl>https://stocktwits.com/CH_Expat/message/630296273</stembedurl>“MLTX results are good everyone being melodramatic about placebo response in second study,” posted another.<stembedurl>https://stocktwits.com/Ataifanboymentalhealthz/message/630283841</stembedurl>As of Friday’s close, MoonLake shares were up more than 14% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is MoonLake Immunotherapeutics Stock Crashing Premarket?

RBC Capital downgraded the stock, calling the results a “near-miss” statistically and warning that the drug’s effect size looked uncompetitive.

Retail chatter spiked for MoonLake Immunotherapeutics late on Sunday after the company announced week 16 results from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in patients with moderate to severe hidradenitis suppurativa (HS).The stock closed at $61.99 on Friday, up 10%, but fell 19% to $50.40 in overnight trading.MoonLake said it plans to discuss the results with regulators to confirm the path toward approval of sonelokimab for HS. The 52-week data is expected&nbsp;to be released in the second quarter of 2026.The company stated that both trials achieved their primary and key secondary goals when data were analyzed using a pre-specified treatment policy method. The studies compared sonelokimab with a placebo, using the HS Clinical Response 75 measure. This measure represents a 75% reduction in abscesses and inflamed nodules with no worsening in draining tunnels.In VELA-1, patients treated with sonelokimab achieved a 17% higher response rate&nbsp;compared to those receiving placebo. In VELA-2, the difference was 9% under the composite analysis. Using the treatment policy approach, both trials showed statistically significant results. The response rates were 35% and 36% for sonelokimab compared with 18% and 26% for placebo.“The higher-than-expected placebo response rate in VELA-2 is disappointing, but we are encouraged by the consistent performance of sonelokimab arms across all endpoints in both studies,” said Kristian Reich, Founder and Chief Scientific Officer at MoonLake.Following the announcement, Stifel downgraded MoonLake to ‘Hold’ from ‘Buy’ and cut its price target to $13 from $77, saying the Phase 3 results were “significantly worse than expected.” Analyst Alex Thompson said the firm’s prior base case of a “clear path to approval in this large market is now off the table in the near term.” Stifel also lowered its probability of success for sonelokimab in hidradenitis suppurativa to 33% from 75%.MoonLake stated that key secondary measures, including pain reduction, quality-of-life improvement, and HiSCR50 responses, also achieved statistical significance. Around 60% of patients&nbsp;treated with sonelokimab experienced a meaningful improvement of at least four points in the Dermatology Life Quality Index (DLQI).The company added sonelokimab's safety profile remained favorable with no new safety signals. Side effects were mainly mild nasal inflammation and headache. No suicidal ideation, liver issues, or major heart problems were reported.All patients will continue receiving treatment until week 52, followed by an open-label extension lasting up to two years.MoonLake said that other studies of sonelokimab are ongoing. These include the Phase 3 VELA-TEEN trial in adolescent HS, the IZAR program in psoriatic arthritis, and the S-OLARIS and LEDA trials in other inflammatory diseases.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume, placing the stock among the top three trending equities on the platform.&nbsp;One user said they had heard talk of a possible Merck buyout for MoonLake Immunotherapeutics that could be discussed during the company’s upcoming call, adding that “lots [was] happening in the offices today.”<stembedurl>https://stocktwits.com/Creisi/message/630272830</stembedurl>Another user commented that investors were “being dramatic” about the data and said they would buy on the dip if they weren’t already fully invested, predicting that the stock “will dip but will bounce back later.”<stembedurl>https://stocktwits.com/ignoreo/message/630271971</stembedurl>MoonLake’s stock has risen 14.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MoonLake Immunotherapeutics Stock Draws Buzz After Skin Drug’s Phase 3 Trial Data — Retail Speculates Buyout, Bigger Gains

MoonLake said it plans to discuss the Phase 3 results with regulators to confirm the path toward approval of sonelokimab for hidradenitis suppurativa, with 52-week data expected in the second quarter of 2026.

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Buy Rating for MoonLake Immunotherapeutics Backed by Strong Prospects for Lead Candidate and Financial Stability

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on MoonLake Immunotherapeutics (MLTX Research Report). The associated p...

TimesSquare Capital Management LLC Has $23.44 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

TimesSquare Capital Management LLC raised its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX  Free Report) by 1,270.7% in the 3rd quarter, according to the company in its most recent...

MoonLake announces significant improvements with Nanobody  sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$8.43
Prev Close	$7.46
Open	$7.53
Dividend Yield	0.00%
50-Day Moving Average	$50.86
Beta	0.47
Avg. Volume	6.32M
PE Ratio	-2.67

52-Week High	$62.75
52-Week Low	$5.95
Market Capitalization	$473.72M
EPS (Annual)	-$1.89
Price to Book	1.34
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MLTX News

MLTX MoonLake Immunotherapeutics